medicine-concept-with-black-doctor-and-old-patient.jpg_s=1024×1024&w=is&k=20&c=rbo8A3J9cJUWNrWq7Jb9dMVPSHNkh8SM19Z216daA4E=
Copyright © 2024 | Practice Business | Intelligent Media Solutions | This site is intended for healthcare professionals only.
See final frame for AE reporting.
For HCPs in GB only.
Adverse events should be reported. Reporting forms and
information can be found at yellowcard.mhra.gov.uk.
Adverse events relating to CSL Seqirus products should also
be reported to Seqirus UK Limited on 01748 828816.
1. Seqirus Data on File, August 2023. SREF–17994.
2. Adjuvanted Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
3. Cell-based Trivalent Influenza Vaccine (surface antigen, inactivated)▼ Summary of Product Characteristics.
Click for Prescribing Information
GBR-AQIV-24-0065 | August 2024
Be the first to comment